Adenovirus Vaccine & VITT: New Study Reveals Antibody Mechanism & Risk Factors
A rare but serious complication following adenovirus-vector COVID-19 vaccination—vaccine-induced immune thrombotic thrombocytopenia (VITT)—has been the subject of a new study published in the New England Journal of Medicine. Researchers from Australia, Germany, and Canada analyzed 100 patients who developed VITT after receiving an adenovirus vaccine, shedding light on the underlying mechanisms driving this adverse reaction.
Understanding VITT
VITT is characterized by blood clots and low platelet counts, a potentially life-threatening condition. Previously, the precise cause remained unclear, though it was known that the body’s own platelets were being mistakenly attacked. The new research reveals that VITT arises from changes in antibodies, transforming harmless antibodies into harmful ones.
The Role of Antibodies
When the immune system encounters a virus, bacteria, or a vaccine mimicking an infection, it produces antibodies. These antibodies mark the invaders for destruction by other immune cells. In the case of adenovirus vaccines, the body generates antibodies targeting components of the vaccine. During this process, antibodies undergo changes to become more effective at neutralizing the threat.
In VITT, a single alteration in some antibodies inadvertently created a harmful antibody. Because parts of platelets structurally resemble the adenovirus, the altered antibody began attacking platelets instead of the virus, leading to clot formation.
Contributing Factors
The research indicates that a single antibody mutation isn’t the whole story. Deeper investigation of patient medical records revealed two additional contributing factors: a history of prior adenovirus infection and specific genetic predispositions.
Most of the 100 VITT patients analyzed exhibited a rapid immune response to the vaccine, suggesting a prior exposure to adenovirus. All patients shared a common gene present in approximately 60% of people of European ancestry. This explains why VITT appeared to be a greater concern in Western countries, where a larger proportion of the population carries this gene and may have pre-existing antibodies.
Individuals with these factors experienced a more intense immune response to the vaccine, increasing the likelihood of the harmful antibody change and subsequent VITT development.
What Could Happen Next
Researchers believe these findings could pave the way for vaccine manufacturers to develop safer formulations that avoid triggering this dangerous reaction. Previous research from the same team suggests the adenovirus component of the vaccine is the primary driver of VITT, rather than other vaccine ingredients. Other studies have also indicated that COVID-19 infection itself, and even mRNA vaccines, can rarely cause blood clots linked to the spike protein.
While the study clarifies the mechanism behind VITT, the fundamental reasons why the body initiates this response remain unknown. According to Dr. Theodore Warkentin, a co-author of the study, the occurrence of VITT is largely a matter of chance, as individual immune responses vary significantly.
Frequently Asked Questions
What is VITT?
VITT, or vaccine-induced immune thrombotic thrombocytopenia, is a rare but serious condition involving blood clots and low platelet counts that can occur after receiving an adenovirus-vector COVID-19 vaccine.
What causes VITT?
VITT is caused by changes in antibodies, which mistakenly attack platelets after vaccination, leading to clot formation. A prior adenovirus infection and a specific genetic predisposition may increase the risk.
Is VITT common?
No, VITT is a very rare occurrence. The study analyzed 100 cases out of millions of adenovirus vaccine doses administered.
How might future vaccines be improved based on this research?